Wisp is building the female longevity stack.
What’s happening: The women’s telehealth company launched a healthy aging vertical, prescribing peptides and other therapeutics for hormonal, immune, and cellular health.
Care hacks. Designed for women navigating hormonal transitions and immune-related issues beyond biohacking, Wisp will offer glutathione, NAD+, and low-dose naltrexone via nasal spray and injectables.
Entering the $80B peptide market, the platform will explore longevity patches, mitochondrial support, and cognitive health pathways alongside its reproductive, metabolic, and menopausal health management.
New path. 75% of women prioritize longevity, but ~50% are unsure what’s best for female physiology. Experiencing disproportionate rates of autoimmune and hormonal conditions, women require dynamic, preventative support across life stages.
Looking beyond menopause, female longevity medicine is emerging as its own category, with wearables, LLMs, and context-aware care enabling action before issues arise.
Looking ahead: With women’s health dictated by life stages, Wisp is betting on holistic care and timed longevity stacks to win lifelong consumers.
